Non-immunoglobulin based protein scaffolds

Current Opinion in Biotechnology

Volumn 22, Issue 6, 2011, Pages 843-848

  Löfblom, John ^a   Frejd, Fredrik Y ^b,c   Ståhl, Stefan ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DEVELOPMENT; COMMON DENOMINATORS; IMMUNOTHERAPEUTICS; MOLECULAR IMAGING; PHARMACOKINETIC PROPERTIES; RECENT PROGRESS; SMALL SIZE; THERAPEUTIC APPLICATION;

AMINO ACIDS; MEDICAL IMAGING; MONOCLONAL ANTIBODIES; PROTEINS; SURFACE PLASMON RESONANCE;

SCAFFOLDS (BIOLOGY);

AFFIBODY MOLECULE; ANTICALIN; BISPECIFIC PROTEIN SCAFFOLD; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; INTERLEUKIN 4 RECEPTOR ALPHA; IODINE 124; KNOTTIN; LIPOCALIN; PEGDINETANIB; SCAFFOLD PROTEIN; SUPERPARAMAGNETIC IRON OXIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BINDING AFFINITY; CHRONIC PAIN; COLORECTAL CARCINOMA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS TUMOR; PATIENT COMPLIANCE; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ANALYSIS;

DIAGNOSTIC IMAGING; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; PROTEINS;

EID: 80053438315     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2011.06.002     Document Type: Review

References (55)

1. Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., Grutter M.G., Plückthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004, 22:575-582.
2. Nygren P.å., Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004, 290:3-28.
3. Grönwall C., Ståhl S. Engineered affinity proteins-generation and applications. J Biotechnol 2009, 140:254-269.
4. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011, 24:3-9.
5. Koide A., Bailey C.W., Huang X., Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998, 284:1141-1151.
6. Xu L., Aha P., Gu K., Kuimelis R.G., Kurz M., Lam T., Lim A.C., Liu H., Lohse P.A., Sun L., et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 2002, 9:933-942.
7. Lipovsek D., Lippow S.M., Hackel B.J., Gregson M.W., Cheng P., Kapila A., Wittrup K.D. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 2007, 368:1024-1041.
8. Hackel B.J., Kapila A., Wittrup K.D. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008, 381:1238-1252.
9. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., Wang J., Ling V., Sun L. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 2006, 13:549-556.
10. Dineen S.P., Sullivan L.A., Beck A.W., Miller A.F., Carbon J.G., Mamluk R., Wong H., Brekken R.A. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008, 8:352.
11. Ackermann M., Carvajal I.M., Morse B.A., Moreta M., O'Neil S., Kossodo S., Peterson J.D., Delventhal V., Marsh H.N., Furfine E.S., et al. Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. Int J Oncol 2011, 38:71-80.
12. Tolcher A.W., Sweeney C.J., Papadopoulos K., Patnaik A., Chiorean E.G., Mita A.C., Sankhala K., Furfine E., Gokemeijer J., Iacono L., et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011, 17:363-371.
13. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010, 584:2670-2680.
14. Feldwisch J., Tolmachev V., Lendel C., Herne N., Sjöberg A., Larsson B., Rosik D., Lindqvist E., Fant G., Höidén-Guthenberg I., et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010, 398:232-247.
15. Zielinski R., Lyakhov I., Jacobs A., Chertov O., Kramer-Marek G., Francella N., Stephen A., Fisher R., Blumenthal R., Capala J. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 2009, 32:817-825.
16. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandström M., Rosik D., Carlsson J., Lundqvist H., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007, 67:2773-2782.
17. Andersen J.T., Pehrson R., Tolmachev V., Daba M.B., Abrahmsén L., Ekblad C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 2011, 286:5234-5241.
18. Jonsson A., Dogan J., Herne N., Abrahmsén L., Nygren P.å. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 2008, 21:515-527.
19. Kronqvist N., Malm M., Gostring L., Gunneriusson E., Nilsson M., Hoiden Guthenberg I., Gedda L., Frejd F.Y., Stahl S., Lofblom J. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 2011, 24:385-396.
20. Lindborg M., Cortez E., Höidén-Guthenberg I., Gunneriusson E., von Hage E., Syud F., Morrison M., Abrahmsén L., Herne N., Pietras K., et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 2011, 407:298-315.
21. Beuttler J., Rothdiener M., Muller D., Frejd F.Y., Kontermann R.E. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug Chem 2009, 20:1201-1208.
22. Puri A., Kramer-Marek G., Campbell-Massa R., Yavlovich A., Tele S.C., Lee S.B., Clogston J.D., Patri A.K., Blumenthal R., Capala J. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 2008, 18:293-307.
23. Myhre S., Henning P., Friedman M., Ståhl S., Lindholm L., Magnusson M.K. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 2009, 16:252-261.
24. Kinoshita M., Yoshioka Y., Okita Y., Hashimoto N., Yoshimine T. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. Contrast Media Mol Imaging 2010, 5:18-22.
25. Gao J., Chen K., Miao Z., Ren G., Chen X., Gambhir S.S., Cheng Z. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 2011, 32:2141-2148.
26. Ahlgren S., Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010, 11:581-589.
27. Miao Z., Levi J., Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2010, 10.1007/s00726-010-0503-9.
28. Kramer-Marek G., Kiesewetter D.O., Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009, 50:1131-1139.
29. Orlova A., Wållberg H., Stone-Elander S., Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
30. Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsén L., Härd T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA 2010, 107:15039-15044.
31. Baum R.P., Prasad V., Muller D., Schuchardt C., Orlova A., Wennborg A., Tolmachev V., Feldwisch J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897.
32. Ahlgren S., Orlova A., Wållberg H., Hansson M., Sandström M., Lewsley R., Wennborg A., Abrahmsén L., Tolmachev V., Feldwisch J. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 2010, 51:1131-1138.
33. Chernomordik V., Hassan M., Lee S.B., Zielinski R., Gandjbakhche A., Capala J. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging 2010, 9:192-200.
34. Schlehuber S., Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins" Drug Discov Today 2005, 10:23-33.
35. Skerra A. Alternative binding proteins: anticalins-harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 2008, 275:2677-2683.
36. Schonfeld D., Matschiner G., Chatwell L., Trentmann S., Gille H., Hulsmeyer M., Brown N., Kaye P.M., Schlehuber S., Hohlbaum A.M., et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci USA 2009, 106:8198-8203.
37. Binder U., Matschiner G., Theobald I., Skerra A. High-throughput sorting of an Anticalin library via EspP-mediated functional display on the Escherichia coli cell surface. J Mol Biol 2010, 400:783-802.
38. Kolmar H. Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr Opin Pharmacol 2009, 9:608-614.
39. Schmidtko A., Lötsch J., Freynhagen R., Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375:1569-1577.
40. Kimura R.H., Levin A.M., Cochran F.V., Cochran J.R. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 2009, 77:359-369.
41. Kimura R.H., Cheng Z., Gambhir S.S., Cochran J.R. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009, 69:2435-2442.
42. Miao Z., Ren G., Liu H., Kimura R.H., Jiang L., Cochran J.R., Gambhir S.S., Cheng Z. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 2009, 20:2342-2347.
43. Jiang L., Miao Z., Kimura R.H., Liu H., Cochran J.R., Culter C.S., Bao A., Li P., Cheng Z. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2011, 38:613-622.
44. Silverman A.P., Levin A.M., Lahti J.L., Cochran J.R. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol 2009, 385:1064-1075.
45. Jiang L., Kimura R.H., Miao Z., Silverman A.P., Ren G., Liu H., Li P., Gambhir S.S., Cochran J.R., Cheng Z. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 2010, 51:251-258.
46. Silverman A.P., Kariolis M.S., Cochran J.R. Cystine-knot peptides engineered with specificities for alpha(IIb)beta(3) or alpha(IIb)beta(3) and alpha(v)beta(3) integrins are potent inhibitors of platelet aggregation. J Mol Recognit 2011, 24:127-135.
47. Sommerhoff C.P., Avrutina O., Schmoldt H.U., Gabrijelcic-Geiger D., Diederichsen U., Kolmar H. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta. J Mol Biol 2010, 395:167-175.
48. Lee C.H., Park K.J., Sung E.S., Kim A., Choi J.D., Kim J.S., Kim S.H., Kwon M.H., Kim Y.S. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc Natl Acad Sci USA 2010, 107:9567-9571.
49. Silverman J., Liu Q., Bakker A., To W., Duguay A., Alba B.M., Smith R., Rivas A., Li P., Le H., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005, 23:1556-1561.
50. Emanuel S.L., Engle L.J., Chao G., Zhu R.R., Cao C., Lin Z., Yamniuk A.P., Hosbach J., Brown J., Fitzpatrick E., et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011, 3:38-48.
51. Osaki A., Toi M., Yamada H., Kawami H., Kuroi K., Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992, 164:323-326.
52. Tsutsui S., Ohno S., Murakami S., Kataoka A., Kinoshita J., Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003, 133:219-221.
53. Friedman M., Orlova A., Johansson E., Eriksson T.L., Höidén-Guthenberg I., Tolmachev V., Nilsson F.Y., Ståhl S. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 2008, 376:1388-1402.
54. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., Widström C., Carlsson J., Tolmachev V., Ståhl S., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
55. Friedman M., Lindström S., Ekerljung L., Andersson-Svahn H., Carlsson J., Brismar H., Gedda L., Frejd F.Y., Ståhl S. Engineering and characterization of a bispecific HER2×EGFR-binding affibody molecule. Biotechnol Appl Biochem 2009, 54:121-131.